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Background: Secreted frizzled-related proteins (SFRPs) are antagonists of the Wnt signaling pathway, which plays a
central role in stem cell maintenance and differentiation of stem cells and hematopoietic progenitors. Epigenetic
downregulation of SFRPs by promoter hypermethylation has been described to be involved in the pathogenesis of
hematopoietic malignancies. There is an association between aberrant Wnt signaling and the established cancer
stem cell concept. In contrast to BCR-ABL1-positive chronic myeloid leukemia CML, BCR-ABL1-negative
myeloproliferative neoplasms (Ph-MPN) are characterized by the frequent occurrence of an autoactivating mutation
in the JAK2 tyrosine kinase (JAK2V617F) or other mutations in the JAK-STAT pathway. However, pathogenetic
mechanisms of JAK2 mutated or unmutated Ph-MPN remain not completely understood. We determined the
promoter methylation status of SFRP-1, -2, -4, and -5 in 57 MPN patient samples by methylation-specific polymerase
chain reaction (PCR) (MSP). JAK2V617F was assessed by allele-specific PCR.
Results: Aberrant methylation among primary MPN samples was 4% for SFRP-1, 25% for SFRP-2, 2% for SFRP-4, and
0% for SFRP-5. Hypermethylation of SFRP-2, which was the most frequently hypermethylated gene in our study,
could not be correlated to any specific MPN subtype. However, we detected a significant correlation between
SFRP-2 methylation and presence of a JAK2V617F mutation (P = 0.008). None of the 10 CML samples showed any
SFRP-methylation.
Conclusions: Our data indicate that epigenetic dysregulation of the Wnt signaling pathway is a common event in
MPN with aberrant methylation of at least one SFRP being detected in 25% of the primary patient samples and in
30% if only accounting for Ph-MPN. A significant correlation between SFRP-2 methylation and presence of
JAK2V617F in our data supports the hypothesis that epigenetic dysregulation may be a complementary mechanism
to genetic aberrations. Aberrant methylation of crucial stem cell maintenance genes seems to contribute to disease
pathogenesis in Ph-MPN.
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Classical myeloproliferative neoplasms (MPN) according
to the WHO classification constitute a group of
hematopoietic malignancies and comprise chronic mye-
loid leukemia (CML), polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis
(PMF). MPN share a common trait of unregulated trili-
neage myeloproliferation and monoclonal hematopoiesis
originating from genetically transformed hematopoietic
stem cells. CML is characterized by the well-known,
disease-causing translocation t(9;22) with the corre-
sponding fusion gene BCR-ABL1. In contrast, BCR-
ABL1-negative MPN (Ph-MPN) present heterogenously
in terms of clinical characteristics and cytogenetic aber-
rations. More than 80% of chromosomal aberrations are
imbalanced changes, with trisomies of chromosomes 8
and 9 being the most frequent aberrations. Further cyto-
genetic findings are chromosomal deletions of 5q, 11q,
13q, 20q, 12p, and Y [1].
The discovery of the Janus kinase 2 (JAK2) V617F mu-
tation in 2005 has modified the understanding of the
molecular basis of Ph-MPN and resulted in a revision of
the WHO diagnostic criteria [2-4]. JAK2 is a receptor-
associated protein tyrosine kinase signaling via the JAK/
signal transducer and activator of transcription (JAK-
STAT) pathway which plays a key role in a wide
spectrum of cellular processes, including proliferation,
survival, and normal function of hematopoietic cells.
JAK2V617F results from a somatic G to T mutation at
nucleotide 1849 in exon 14 with consecutive Val617Phe
substitution. The mutation affects the non-catalytic
pseudo-kinase domain of the JAK2 protein and is re-
sponsible for the loss of autoregulatory functionality
with constitutive signaling and subsequent hypersensitiv-
ity to hematopoietic growth factors. JAK2V617F is by far
the most prevalent mutation in Ph-MPN with this point
mutation being detected in more than 95% of patients
with PV, 50% of patients with ET, and 50% of patients
with PMF [2,5]. Despite detection of JAK2V617F in
other myeloid diseases, JAK2V617F exhibits a broad spe-
cificity to patients with myeloid neoplasms. In addition
to the JAK2V617F mutation, pathogenesis of the MPN
has evolved from a simple to a complex model with a
number of novel mutations that have been described in
chronic or blast-phase Ph-MPN. The most prevalent are
mutations in JAK2 exon 12, Myeloproliferative Leukemia
Virus (MPL), TET oncogene family member (TET2), Add-
itional Sex Combs-like 1 (ASXL1), Casitas B-lineage
lymphoma proto-oncogene (CBL), Isocitrate dehydrogen-
ase (IDH)1 and 2, and IKAROS family zinc finger 1
(IKZF 1) [6]. However, questions remain concerning the
initial disease-causing event in Ph-MPN, the develop-
ment of phenotypic distinct diseases and the mechan-
isms leading to transformation in acute myeloidleukemia (AML). There is increasing evidence that epi-
genetic alterations might contribute to the pathogenetic
and phenotypic variety of MPN [7].
Epigenetic alterations have been shown to play an im-
portant role in tumorigenesis [8]. In particular, aberrant
methylation of CpG islands within gene promoter
regions is associated with transcriptional inactivation
and represents an important mechanism of gene silen-
cing in the pathogenesis of hematopoietic malignancies
[9,10]. Epigenetic disturbances are postulated to be a
complementary or alternative mechanism to genetics
[11,12]. Aberrant CpG island methylation in MPN has
been reported for p15 and p16 (cell cycle regulation), as
well as for retinoic acid receptor beta 2 (RARβ2) and
Abelson (ABL) [13,14]. Furthermore, the stromal cell-
derived factor-1 (SDF-1) receptor CXCR4 is abnormally
downregulated in CD34-positive hematopoietic progeni-
tor cells that constitutively circulate in PMF patients.
Functional reconstitution with demethylating agents in
combination with the histone deacetylase (HDAC) in-
hibitor results in reduction of in vitro generated
JAK2V617F mutated cells [15]. Hypermethylation of the
JAK-STAT inhibitor suppressor of cytokine signaling
(SOCS) 1 has been shown by independent groups and
downregulation of SOCS-3 as well as src homology region
2 domain-containing phosphatase 1 (SHP1) has been
found to be associated with promoter methylation in
MPN patients [12,16] Further evidence of involvement
of epigenetic dysregulation in MPN pathogenesis evolve
from the findings of loss-of-function mutations in en-
hancer of zeste homolog 2 (EZH2), ASXL1 and TET2
with resulting deregulation in both DNA methylation
and chromatin structure [17].
To gain additional information about the prevalence
and pathogenetic relevance of epigenetic changes as
complementary or alternative mechanism in the patho-
genesis in MPN, we determined the promoter methyla-
tion status of secreted frizzled-related proteins (SFRPs).
SFRP-1, -2, -4, and -5 possess a CpG island in the pro-
moter region and are antagonists of the Wnt signaling
pathway. Consistent with the key functions of the Wnt
pathway in stem cell maintenance and differentiation of
hematopoietic progenitors, epigenetic downregulation of
SFRPs has been described in hematopoietic malignancies
[18,19].
Results
Methylation analysis of SFRP-1, -2, -4 and -5
We first analyzed the methylation status of SFRP-1, -2,
-4, and -5 promoter regions by MSP in the human
MPN-derived cell lines SET-2 and GDM-1. Methylation
was found for SFRP-1, -2, and -5 in GDM-1 cells
(Figure 1). None of the four genes showed aberrant
methylation in SET-2 cells. Methylation-associated gene
Figure 1 MSP analysis of the four SFRP genes in MPN-derived cell lines and normal peripheral blood (PB). In vitro methylated DNA (IVD)
and water served as controls. Lane U, amplified product with primers recognizing unmethylated SFRP-1, -2, -4, and -5 sequences. Lane M,
amplified product with primers recognizing methylated SFRP-1, -2, -4, and -5 sequences.
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been published previously [18]. Owing to the func-
tional importance of the Wnt pathway in several
hematopoietic malignancies, we then investigated the
methylation status of the SFRP promoter regions in
PB and BM from 57 primary MPN patient samples
obtained at diagnosis or during follow-up. Table 1
gives an overview of the characteristics of the patient
cohort. Representative MSP-results for SFRP-1, -2, -4,
and -5 are shown in Figure 2.
The frequency of aberrant methylation among primary
MPN patient samples was 4% (2/57) for SFRP-1, 25%
(14/57) for SFRP-2, 2% (1/57) for SFRP-4, and 0% (0/57)
for SFRP-5. Aberrant methylation of at least one of the
SFRP genes was detected in all Ph-MPN subtypes. In
contrast, no methylation of any of the SFRPs has been
detected in CML samples. Among the Ph-MPN subtypes
we found methylation of any SFRP in 30% (3/10) PV-Table 1 Characteristics of the patient cohort
JAK2 Age Gender WBC (
mut wt m f
CML (n = 10) 0 10 55 9 1 81
PV (n = 10) 8 2 56 4 6 12
ET (n = 10) 5 5 69 3 7 8
MF (n = 27) 14 13 67 12 15 10
Total 27 30 66 28 29 11
Median values for age, WBC, Hb, Plt, Blasts, LDH. CML, Chronic myeloid leukemia, E
MF, myelofibrosis; mut, positive for JAK2V617F; plt, platelet count; PV, polycythemiapatient samples, 40% (4/10) ET-patient samples, and
26% (7/27) MF-patient samples. Regarding the rare
methylation of SFRP-4 and -5, only SFRP-1 and -2 were
considered for further statistical analyses. We did not
see any significant association between SFRP-2 methyla-
tion and MPN subtype. However, there was an associ-
ation of SFRP-1 hypermethylation and diagnosis of ET
(2/2 SFRP-1 promoter methylations in ET patients, P =
0.02). We could not show any correlation between
SFRP-2 methylation and platelet count, peripheral blast
cell count, red blood cell count, white blood cell count
(WBC), or lactate dehydrogenase in PB. Furthermore, a
history of cytostatic therapy did not influence SFRP-2
methylation frequency in our patient cohort.
JAK2 mutation analysis
Using allele-specific PCR, 47% (27/57) of the patients
showed a signal corresponding to the JAK2 G >T109/L) Hb (g/L) Plt (109/L) Blasts (%) LDH (U/L)
.3 107 219 1 599
.4 133 370 0 259
.2 130,5 770 0 267
.1 104,5 376 0,5 431
.7 114 338 0 369
T, essential thrombocythemia; Hb, hemoglobin; LDH, lactate dehydrogenase;
vera; WBC, white blood cell count; wt = negative for JAK2V617F.
Figure 2 Representative MSP analysis of the four SFRP genes in MPN patient samples. DNA from Raji cells and water served as controls.
Lane U, amplified product with primers recognizing unmethylated SFRP-1, -2, -4, and -5 sequences. Lane M, amplified product with primers
recognizing methylated SFRP-1, -2, -4, and -5 sequences. Patient sample #1546 methylated at the SFRP-2 promoter, patient sample #1376
methylated at the SFRP-1 promoter.
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patients had a JAK2 mutation. Among the MF samples,
52% (14/27) carried the mutation. In accordance with
expectations we did not detect JAK2V617F in CML pa-
tient samples. We could not show any correlation be-
tween JAK2V617 mutation and laboratory findings.
Importantly, there was no association between previous
cytostatic therapy and presence of JAK2V617F. Repre-
sentative results of the allel-specific PCR are shown in
Figure 3.
Epigenetic and genetic changes
Of the two patient samples methylated at the SFRP-1
promoter, one carried the mutation whereas the other
one was wild-type JAK2. In contrast, of the 14 patients
with aberrant methylation of SFRP-2, 78.6% (11/14) wereFigure 3 Representative JAK2 mutation analysis of MPN patient samp
for the mutant allele, whereas the 364 bp product amplifying both mutant
healthy donor (#1287) was used as a negative control. DNA from a patient
(#1222, mutation verified by sequencing). In a dilution series of DNA from
the sensitivity of the PCR could be shown to be at least 1/64. M = DNA lad
JAK2V617F mutation.positive for the JAK2V617F mutation whereas 21.4% (3/
14) showed wild-type JAK2. Thus, there is a significant
correlation of SFRP-2 methylation occurring in associ-
ation with a mutated status at JAK2 (P = 0.008). Table 2
gives a view of concomitant JAK2 mutation and SFRP-2
promoter methylation in patients with MPN.
Discussion
To the best of our knowledge, no data have been pub-
lished so far about aberrant CpG island hypermethyla-
tion of SFRP-1, -2, -4, and -5 in the context of
JAK2V617F in Ph-MPN.
In contrast to CML, a number of novel mutations have
been described in BCR-ABL1-negative MPN. Among
those are mutations involving JAK2, MPL, TET2, ASXL1,
CBL, IDH, and IKZF1 [17,20]. Wnt signaling plays anles by allele-specific PCR. The 203 base pairs (bp) product is specific
and wild-type alleles serves as an internal PCR control. DNA from a
with homozygous JAK2V617F mutation served as a positive control
a patient with a homozygous JAK2V617F mutation with normal DNA,
der. Patient samples #1537, #1541, #1542, #1543, and #1546 carry a
Table 2 Concomitant JAK2 mutation and SFRP-2
hypermethylation in MPN patients
CML (n = 10) PV (n = 10) ET (n = 10) MF (n = 27)
SFRP-2 U M U M U M U M
JAK2, wt 10 0 1 1 4 1 12 1
JAK2V617F 0 0 6 2 2 3 8 6
CML, chronic myeloid leukemia; ET, essential thrombocythemia; M, methylated;
MF, myelofibrosis; PV, polycythemiavera; U, unmethylated; wt = negative for
JAK2V617F.
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ferentiation and proliferation of hematopoietic progeni-
tor cells. Recently, it has been reported that Wnt
signaling could be one of the mechanisms that shape a
niche in the bone marrow supportive of hematopoiesis
[21]. Since aberrant activation of the Wnt pathway has
been demonstrated to contribute to leukemogenesis and
until now, in contrast to solid tumors, no activating
mutations in the genes of the Wnt pathway have been
described in myeloid or lymphatic malignancies, we
investigated epigenetic regulation of SFRP-1, -2, -4, and
-5 as negative regulators of Wnt signaling. Our data in-
dicate that CpG island hypermethylation of SFRP genes
is a frequent event in Ph-MPN with aberrant methyla-
tion of at least one of the four genes being detected in
30% of the primary patient samples. Compared to the
SFRP methylation patterns in other hematopoietic ma-
lignancies, aberrant promoter methylation in our study
occurred less frequently than in AML [18]. We could
show a preferential hypermethylation of SFRP-1 (4%)
and of SFRP-2 (25%), in particular. This is in contrast to
the methylation frequency of SFRP genes in acute
lymphatic leukemia (ALL) [22], where a more balanced
methylation frequency of the four genes could be shown,
but confirms findings in AML showing a preferential
hypermethylation of SFRP-1 (29%) and SFRP-2 (19%).
We could show a significant association of SFRP-1
hypermethylation and diagnosis of ET. Regarding the
limited number of patient samples methylated at the
SFRP-1 promoter (2/57), those results require further
confirmation. Furthermore, a study in 52 ET samples did
not find any evidence of hypermethylation of soluble
Wnt inhibitors [23], whereas our analysis, also using
MSP and the same primer sequences, revealed a rate of
40% of ET samples being methylated.
In contrast to SFRP-1, SFRP-2 hypermethylation in
our study occurred in all Ph-MPN subtypes without any
association with a specific entity. However, there was a
significant correlation between aberrant SFRP-2 pro-
moter methylation and the presence of JAK2V617F.
The autoactivating JAK2V617F mutation is responsible
for constitutive signaling of the JAK2 protein with subse-
quent hypersensitivity to hematopoietic growth factors
[3]. When comparing the incidence of the JAK2V617Fmutation and the frequency among the MPN subtypes
with published data, the relative distribution (80% PV,
50% ET, 52% MF) we obtained in our study is in accord-
ance with previous reports [5]. Limited data are available
about epigenetic disturbances in MPN. Increasing evi-
dence suggests that loss-of-function mutations in genes
involved in epigenetic regulation, TET2, ASXL1, and
EZH2, as well as JAK2V617F-mediated phosphorylation
of protein Arg N-methyltransferase (PRMT5) may play a
role in disease pathogenesis, either as ‘pre-JAK2 events’
or occurring in late phase disease [17,24-26].
Aberrant CpG island methylation has been reported
for ABL, p14, p15, p16, RARß2 [13], and SDF1 receptor
CXCR4 [15]. SOCS proteins are the most thoroughly
studied inhibitors of JAK-STAT pathways. Silencing of
SOCS-1 and -3 in association with promoter hyper-
methylation has been reported by different groups
[12,16,27]. However, Capello et al. reported that SOCS-3
methylation was more frequent among JAK2V617F-
negative patients. Nevertheless, the results suggest that
epigenetic inactivation seems to play a role in Ph-MPN.
Epigenetics might be a complementary or alternative
mechanism to the JAK2V617F mutation in the patho-
genesis of Ph-MPN, leading to dysregulation of JAK-
STAT signal transduction and thus to growth factor
hypersensitivity. Our findings are in accordance with this
hypothesis showing a trend towards an association be-
tween JAK2V617F and SFRP-2 hypermethylation, thus,
an association between genetic and epigenetic aberra-
tions. Interesting in this context is the comparison of
Ph-MPN with CML. The identified disease-causing mu-
tation in CML which codes for a fusion-protein with
tyrosine kinase activity provides a potential therapeutic
target. The clinical success of the tyrosine kinase inhibi-
tor imatinib suggests that the mutation might be one of
the main events leading to the pathogenesis of CML.
However, regarding the reported Wnt pathway activation
in CML cancer stem cells [28] and the reported correl-
ation of SFRP-1 promoter methylation and resistance to
imatinib [29] the impact of hypermethylation-associated
gene silencing in CML in contrast to Ph-MPN has to be
further elucidated. According to our study, SFRP pro-
moter hypermethylation in CML seems to be an uncom-
mon event.
Conclusion
Despite the discovery of the nearly disease specific
JAK2V617F-mutation and its capacity to induce myelo-
proliferative disease-like phenotypes in murine models
[30], additional genetic or epigenetic events are thought
to play an important role in disease initiation. Further-
more, development of three distinct entities from one
known mutation has to be explored. Since our patient
cohort only consisted of 57 samples and was
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conclusion can be retained from these data neither
regarding the pathogenetic interrelationship of genetic
and epigenetic events, nor the phenotypic differences be-
tween Ph-MPN subtypes or resulting treatment options
in a group of diseases with allogenic stem cell trans-
plantation being the only curative concept. Tyrosine
kinases are essential therapeutic targets in several dis-
eases and development of inhibitors of JAK2 are being
tested in clinical studies. Targeting the epigenome might
be a worthwhile effort to complement existing or newly
developed therapeutic strategies [6].Methods
Human tissue samples
All samples from patients were collected after informed
consent was given. Thirty-four peripheral blood (PB)
and 23 bone marrow (BM) specimens were obtained
during routine clinical assessment between 1996 and
2007 of 57 adult patients with MPN without any evi-
dence for leukemic transformation. According to stand-
ard criteria [31], patients were classified as having CML
(n = 10), ET (n = 10), PV (n = 10), and MF (n = 27).
The collection of patient samples for analysis of genetic
and epigenetic changes was approved by the local ethics
committee. DNA extraction was performed from unse-
lected cells from BM, when available, or PB. Additionally,
we examined the methylation status of MPN-derived cell
lines GDM-1 and SET-2.Methylation analysis of SFRP-1, -2, -4, and -5
BM and PB mononuclear cells were isolated by density
gradient centrifugation according to standard procedures
prior to further analysis. Assessment of peripheral blood
mononuclear cells is appropriate regarding the high sen-
sitivity of the applied MSP methods (0.1%) [32]. For the
DNA isolation the QIAmpW DNA Mini Kit (Quiagen,
Hilden, Germany) was used according to the manufac-
tures instructions. The methylation status of SFRP-1, -2,
-4, and -5 was investigated by MSP. Approximately 1 μg
of DNA was chemically modified by sodium bisulfit
treatment prior to MSP. This assay converts all
unmethylated cytosins to uracil but leaving the methy-
lated cytosins unaffected. Subsequently, amplification
with primers specific for methylated vs. unmethylated
DNA was performed [32]. MSP primer sequences and
reaction conditions for SFRP-1, -2, -4, and -5 have been
described previously [33]. The primer specific reaction
temperatures were 60°C for SFRP-1 and -2, 62°C for
SFRP-4 and 63°C for SFRP-5. For every MSP reaction,
in vitro methylated DNA (IVD) or the Burkitt lymphoma
cell line Raji served as positive and normal PB from
healthy volunteers served as negative controls. PCRproducts were separated on 2.5% agarose gels and visua-
lized by ethidium bromide staining.
JAK2 mutation analysis
The mutational status of the JAK2 gene was assessed by
allele-specific PCR. Primers and reaction conditions used
were previously described [2]. After amplification, the
presence of a JAK2V617F mutation was visualized under
UV light on 2% agarose gels after ethidium bromide
staining. In a 1:2 dilution series of DNA from a patient
with a homozygous JAK2V617F mutation with normal
DNA, the sensitivity of the PCR was shown to be at least
1/64. Direct sequencing of the samples mutated by allele
specific PCR confirmed the JAK2V617F mutation in
most of the patients and is a proof for a sufficient pro-
portion of clonal cells in the starting material (data not
shown). DNA from a patient with a homozygous
JAK2V617F mutation was used as a positive control.
DNA from a healthy donor was used as a negative con-
trol for every PCR reaction.
Statistical methods
Correlations between variables were analyzed using the
Fisher’s exact two-sided test and the two-sided Student’s
t-test, respectively. All calculations were performed
using the SAS statistical software version 9.1.3.
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